Muhammad Arsalan Bakhtiar

Featured in: Favicon

Articles

Assessment of postoperative death and 5 years overall survival in patients in the West with curative gastric adenocarcinoma who undergo the experimental D2 gastrectomy as compared to the patients who undergo conventional D1 gastrectomy; a systematic revie

Jan 13, 2024 | ejso.com | Muhammad Arsalan Bakhtiar |Mahnoor Mahnoor |Muhammad Bajwa |Rabeea Ahmed

Background: D2 gastrectomy for gastric adenocarcinoma is used in Japan with good outcomes related to mortality and morbidity. In contrast, Western European countries employ D1 gastrectomy for gastric adenocarcinoma because trials have shown that D2 gastrectomy is associated with high adverse events.
A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)

Sep 7, 2023 | mdpi.com | Akshit Chitkara |Muhammad Arsalan Bakhtiar |Ibrahim Halil Sahin |Ibrahim Şahin |Dennis J. Hsu

3. Results 3.1. Study CharacteristicsTwo of the six trials selected evaluated trastuzumab deruxtecan, and one evaluated trastuzumab plus lapatinib. One trial evaluated pertuzumab plus trastuzumab emtansine, while one evaluated trastuzumab plus tucatinib, and one evaluated trastuzumab plus pyrotinib (Table 2). Regarding prior lines of treatment, the median number of prior lines was two and three in two trials and four and five in one trial each.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.